Jim Cramer Backs Clover Health as Spec Play, Still Favors UNH and CVS
Cramer calls Clover Health a reasonable speculative bet while maintaining his preference for UnitedHealth and CVS as core health-sector holdings.
CNBC's Jim Cramer acknowledged Clover Health as a worthwhile speculative pick, signaling cautious optimism about the smaller insurer while stopping well short of recommending it as a primary portfolio holding. His comments reflect the ongoing tension investors face when choosing between high-risk, high-reward health-care bets and established giants with steadier fundamentals.
Cramer's continued endorsement of UnitedHealth Group and CVS Health underscores his preference for companies with proven revenue streams, diversified business models, and the scale needed to navigate regulatory and competitive pressures in the health-care sector. Both firms operate across insurance, pharmacy, and health-services segments, offering exposure to multiple growth drivers simultaneously.
Read more Jim Cramer Backs Ingredion as Future Powerhouse After Tate & Lyle Deal →
Clover Health, by contrast, occupies a far more speculative corner of the market. The Medicare Advantage-focused insurer has faced persistent questions about profitability and competitive positioning, making it a name better suited for risk-tolerant investors willing to absorb volatility in exchange for potential upside if the company's technology-driven care model gains broader traction.
Cramer's framing — good speculation, but not a replacement for blue-chip health names — mirrors a broader analyst caution around smaller managed-care disruptors at a time when the entire sector is contending with rising medical costs, reimbursement uncertainty, and shifting federal policy around Medicare Advantage rates. Investors should weigh those macro headwinds before adding any health insurer to their portfolios.
Continue reading at Yahoo Finance.
